Scinovex
articleTop 1% cited

Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association

Arteriosclerosis Thrombosis and Vascular Biology · 2022 · Vol. 42(6) · pp. e168–e185
P. Barton DuellFrancine K. WeltyMichael MillerAlan ChaitGmerice HammondZahid AhmadDavid E. CohenJay D. HortonGregg S. PressmanPeter P. Toth

Abstract

Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is believed to affect >25% of adults worldwide. Unless specific testing is done to identify NAFLD, the condition is typically silent until advanced and potentially irreversible liver impairment occurs. For this reason, the majority of patients with NAFLD are unaware of having this serious condition. Hepatic complications from NAFLD include nonalcoholic steatohepatitis, hepatic cirrhosis, and hepatocellular carcinoma. In addition to these serious complications, NAFLD is a risk factor for atherosclerotic cardiovascular disease, which is the principal cause of death in patients with NAFLD. Accordingly, the purpose of this scientific statement is to review the underlying risk factors and pathophysiology of NAFLD, the associations with atherosclerotic cardiovascular disease, diagnostic and screening strategies, and potential interventions.

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health EffectsCardiovascular Disease and AdiposityNonalcoholic fatty liver diseaseDiseaseFatty liverRisk factorPathophysiologyAtherosclerotic cardiovascular diseaseStatement (logic)Liver disease

MeSH terms

Heart Disease Risk FactorsAdultAmerican Heart AssociationCardiovascular DiseasesHumansLiverRisk FactorsAtherosclerosisNon-alcoholic Fatty Liver Disease
Citations
596
FWCI
85.54
field-weighted impact
References
157
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.